ERBB2 and neoplasm: Analysis of the biodistribution data indicated that the uptake of [89Zr]Zr-trastuzumab and [111In]In-IgG in the HER2-negative tumours was statistically indistinguishable (12.2 ± 3.8 and 12.7 ± 4.7%ID/g, respectively; P > 0.05).